Literature DB >> 21963276

Simultaneous determination of asperosaponin VI and its active metabolite hederagenin in rat plasma by liquid chromatography-tandem mass spectrometry with positive/negative ion-switching electrospray ionization and its application in pharmacokinetic study.

He Zhu1, Li Ding, Shailendra Shakya, Xiemin Qi, Linlin Hu, Xiaolin Yang, Zhonglin Yang.   

Abstract

A new liquid chromatography-tandem mass spectrometry (LC-MS/MS) method operated in the positive/negative electrospray ionization (ESI) switching mode has been developed and validated for the simultaneous determination of asperosaponin VI and its active metabolite hederagenin in rat plasma. After addition of internal standards diazepam (for asperosaponin VI) and glycyrrhetic acid (for hederagenin), the plasma sample was deproteinized with acetonitrile, and separated on a reversed phase C18 column with a mobile phase of methanol (solvent A)-0.05% glacial acetic acid containing 10 mM ammonium acetate and 30 μM sodium acetate (solvent B) using gradient elution. The detection of target compounds was done in multiple reaction monitoring (MRM) mode using a tandem mass spectrometry equipped with positive/negative ion-switching ESI source. At the first segment, the MRM detection was operated in the positive ESI mode using the transitions of m/z 951.5 ([M+Na](+))→347.1 for asperosaponin VI and m/z 285.1 ([M+H](+))→193.1 for diazepam for 4 min, then switched to the negative ESI mode using the transitions of m/z 471.3 ([M-H](-))→471.3 for hederagenin and m/z 469.4 ([M-H](-))→425.4 for glycyrrhetic acid, respectively. The sodiated molecular ion [M+Na](+) at m/z 951.5 was selected as the precursor ion for asperosaponin VI, since it provided better sensitivity compared to the deprotonated and protonated molecular ions. Sodium acetate was added to the mobile phase to make sure that abundant amount of the sodiated molecular ion of asperosaponin VI could be produced, and more stable and intensive mass response of the product ion could be obtained. For the detection of hederagenin, since all of the mass responses of the fragment ions were very weak, the deprotonated molecular ion [M-H](-)m/z 471.3 was employed as both the precursor ion and the product ion. But the collision energy was still used for the MRM, in order to eliminate the influences induced by the interference substances from the rat plasma. The validated method was successfully applied to study the pharmacokinetics of asperosaponin VI and its active metabolite hederagenin in rat plasma after oral administration of asperosaponin VI at a dose of 90 mg/kg. Copyright Â
© 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21963276     DOI: 10.1016/j.jchromb.2011.09.014

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  4 in total

1.  Pharmacokinetics study of asperosaponin VI and its metabolites cauloside A, HN saponin F and hederagenin.

Authors:  Er-Wei Liu; Jia-Long Wang; Li-Feng Han; Yan-Xu Chang; Tao Wang; Yan Huo; Lei Wang; Xiu-Mei Gao
Journal:  J Nat Med       Date:  2014-03-11       Impact factor: 2.343

2.  Influence of Nutritional Status on the Absorption of Polyphyllin I, an Anticancer Candidate from Paris polyphylla in Rats.

Authors:  Feng-Ling Yu; Wei-Liang Gong; Fang-Jiang Xu; Jun-Wen Wu; Shailendra Shakya; He Zhu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-10       Impact factor: 2.441

Review 3.  Current knowledge and development of hederagenin as a promising medicinal agent: a comprehensive review.

Authors:  Jia Zeng; Ting Huang; Man Xue; Jianxing Chen; Linglin Feng; Ruofei Du; Yi Feng
Journal:  RSC Adv       Date:  2018-07-03       Impact factor: 4.036

4.  Separation and Quantification of Selected Sapogenins Extracted from Nettle, White Dead-Nettle, Common Soapwort and Washnut.

Authors:  Magdalena Ligor; Anna Kiełbasa; Ileana-Andreea Ratiu; Bogusław Buszewski
Journal:  Molecules       Date:  2021-12-20       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.